Combination therapy

Delve into the world of Combination therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Combination therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure
CompanyDrug

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that its partner AstraZeneca plc (NYSE: AZN) has submitted a New Drug Application (NDA) to the U.S. FDA for the combination therapy…

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial

CompanyDeals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

CompanyDeals

Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies

CompanyDeals

Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors

CompanyDrug

RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor

CompanyDrug

ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors

CompanyDeals

Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment

CompanyDrug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study

Show More